Introduction
Since the initial descriptions of adaptive immune responses against HIV in infected individuals, research efforts in the HIV field have put a strong emphasis on CD8 T-cell (CTL) responses with the goals of understanding the capacity of elite controllers to suppress viral replication and of developing of a CTL-based vaccine. The recent outcomes of the STEP and the RV144 clinical trials [1,2,3 ] highlighted the need for a rational vaccine design that will aim at inducing broader and stronger combined humoral and cell-mediated immune responses [4] . Numerous studies in animal models and data in humans provide strong evidence that CD4 help in vivo is critical for the generation of effective CTL and B-cell responses [5] and for mobilizing CTLs to infected mucosa [6 ] . Although the preferential infection of HIV-specific CD4 T cells raised the concern that this subset might fuel viral replication rather than contribute to its control [7] , this relative increase is small and the large majority of HIV-specific CD4 T cells are not infected in vivo, even in the presence of high viral loads [7] . It is thus likely that vaccine-induced HIV-specific CD4 T cells will significantly contribute to effective immunotherapies against HIV.
Here, we review recent studies that examined differences in HIV-specific CD4 T-cell responses between elite controllers and patients with progressive infection. We also discuss data that shed light on mechanisms of CD4 T-cell help and its functional impairment. Finally, we comment on virus-specific CD4 T-cell responses generated by HIV vaccines.
Differences between in HIV-specific CD4 T-cell responses of HIV controllers and individuals with progressive infection
Virus-specific CD4 T-cell responses are impaired early in the course of HIV disease. The weak or absent HIVspecific proliferative CD4 T-cell responses that are a hallmark of progressive HIV infection [8-10] were subsequently shown to be largely caused by loss of functions, in particular defective IL-2 secretion, and not physical deletion [11] [12] [13] . HIV-specific CD4 T-cell responses are detectable in the large majority of HIV-infected individuals with current techniques (e.g. flow cytometry) but their magnitude is typically low and several fold smaller than the magnitude of CTL responses in the same patients [11] . Studies showing that HIV-specific CD4 T cells in elite controller patients maintained proliferative capacity in vitro compared with untreated individuals with progressive disease (chronic progressors) [14] [15] [16] suggested that these responses might have unique characteristics. Consistent with these findings, HIV-specific CD4 T cells of elite controllers were shown to produce more IL-2 and to be more polyfunctional than those of chronic progressors patients [11, 13, 17, 18] , whereas the magnitude of HIV-specific CD4 T-cell responses measured by IFN-g secretion did not correlate with viremia [11] . Subsequent data comparing elite controllers, chronic progressors, and patients with optimally controlled viral load on antiretroviral therapy (cART) demonstrated that the differences in proliferative capacity, IL-2 secretion, and phenotypic markers observed were at least in part the consequence, and not the cause, of low viral load [17, [19] [20] [21] .
Recent studies, however, showed that HIV-specific CD4 T cells in elite controllers and chronic progressors individuals present differences that cannot be restored by antiviral therapy alone. Involvement of the gut-associated lymphoid tissue (GALT) is thought to be critical in HIV pathogenesis [22] [23] [24] [25] . Ferre et al.
[26 ] compared HIV Gag-specific CD4 T-cell responses (measured by production of the cytokines IFN-g, IL-2, TNF-a, and MIP-1b) in peripheral blood and rectal mucosa from HIV controllers, chronic progressors, and ART-controlled individuals. HIV-specific CD4 T-cell responses were generally higher in the rectal mucosa than in peripheral blood. The total magnitude of mucosal HIV-specific CD4 T-cell responses in controllers did not differ significantly from chronic progressors patients, but was higher than in ART-controlled subjects. This finding is consistent with previous findings in peripheral blood mononuclear cell (PBMC) showing a decrease in the number of virusspecific, HIV-specific CD4 T cells after control of viral load by ART [27, 28] . This dependency of dysfunctional T cells on antigen persistence is consistent with various animal models [29] . The maintenance of virus-specific CD4 T-cell responses in elite controllers suggests a more functional, long-lived memory T-cell population and/or a better capacity to respond to small antigen load. Additionally, the same study [26 ] showed that controllers had higher frequency of mucosal HIV-specific polyfunctional CD4 T cells than chronic progressors and ART-controlled individuals. Further tissue studies are required to expand these data, as studies in animal models showed significant organ-specific differences in T-cell responses [29] .
Focusing on immunodominant HIV CD4 T-cell epitopes, Vingert et al.
[30 ] examined growth kinetics, Vb repertoire, and avidity for antigen of HIV-specific CD4 T-cell lines derived from PBMC of elite controllers, ART-controlled, and chronic progressors patients. They identified a subpopulation of HIV-specific CD4 T cells in elite controllers endowed with a higher functional avidity compared with noncontrollers. These differences were noted in responses specific for an HIV Gag p24 peptide previously shown to be immunodominant and presented by multiple HLA Class II alleles [31, 32] . Using HLA-Class II tetramers, the authors further demonstrated a higher TCR binding avidity to the HLA-peptide complex in elite controllers. This capacity of HIV-specific CD4 T cells in elite controllers to respond to minimal amounts of antigen may contribute to higher magnitudes of HIV-specific CD4 T-cell responses in elite controllers compared with ART-controlled individuals [11, 17, 26 ] .
Some previous studies suggested that HLA-DRB1Ã13 could be associated with immune control [33, 34] . Ferre et al. [26 ] found that controllers carrying the class II alleles HLA-DRB1Ã13 and/or HLA-DQB1Ã06 had the most robust HIV-specific CD4 T-cell responses and that individuals who had both alleles showed highly polyfunctional mucosal CD4 T cells compared with those that had HLA-DQB1Ã06 alone or other class II alleles. However, the association of specific HLA Class II alleles with elite controller status remains to be confirmed in larger studies. While a recent large GWAS study [35 ] confirmed the association of several HLA Class I alleles including B57 and B27 with viral control, no HLA Class II association reached genome-wide significance. Whereas mutations in epitopes targeted by CD4 T cells during early HIV infection have been described [36] , no direct evidence
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Key points
HIV-specific CD4 T cells will likely be an important component of an effective HIV vaccine. An increasing number of qualitative differences in HIV-specific CD4 T cells between controllers and progressors are being identified, and some of these differences are not fully corrected by control of viral load on therapy. T-cell exhaustion caused by chronic infection is governed by multiple inhibitory receptors whose expression patterns differ between HIV-specific CD4 and CD8 T cells. IL-21 secretion by HIV-specific CD4 T cells is decreased in progressive HIV infection, which may contribute to both B-cell and CD8 T-cell impairment.
It is likely that the renewed interest in HIV-specific CD4 T cells will lead in a near future to the development of novel vaccine reagents that generate more robust and effective HIV-specific CD4 T-cell responses.
of CD4 T cell-driven viral escape or HLA Class II footprint has been documented thus far. Clearly, further studies are required to better determine the link between specific HLA Class II molecules and characteristics of HIV-specific CD4 T-cell responses.
Inhibitory receptors and HIV-specific CD4 T-cell exhaustion
An important factor in the lack of pathogen clearance in chronic infection is T-cell exhaustion, defined as the progressive loss of functions in antigen-specific T cells leading to ineffective T-cell response [37] . T-cell exhaustion is due both to progressive damage to the cellular machinery and to active suppression of functions [38] , and is in part mediated by negative regulatory pathways that play an important role in maintaining peripheral tolerance and avoid excessive immune activation in physiologic conditions. T-cell exhaustion is a gradual process, with some functions being lost early (proliferation, IL-2 secretion), while others, like IFN-g secretion, are lost at an advanced stage of impairment [5], consistent with the characteristics of HIV-specific CD4 T-cell responses at different disease stages.
Whereas several studies have investigated the role of programmed death-1 (PD-1), an inhibitory molecule of the B7:CD28 family, in HIV-specific CD8 T-cell dysfunction [39] , less is known on the role of immunoregulatory networks in HIV-specific CD4 T-cell exhaustion [40] . PD-1 is upregulated on HIV-specific CD4 T cells [41, 42] and its expression level correlated with viremia [41] . Blockade of the PD-1 pathway with a PD-L1 blocking antibody increased HIV-specific CD4 T-cell proliferation, with significant variability among the small cohorts of patients investigated [41] [42] [43] . The observation that CTLA-4, another molecule of the B7:CD28 family, was also upregulated on HIV-specific CD4 T cells and mediated a reversible dysfunction of these responses [42, 44] demonstrated that multiple inhibitory receptors co-regulate virusspecific T-cell impairment [40] . Kassu et al. [45] recently extended these observations by examining expression of PD-1, CTLA-4 and another regulatory receptor, TIM-3, which has been shown to impair HIV-specific CD8 T-cell responses [46] . Co-expression of all three receptors was more strongly correlated with viral load compared with the expression of each receptor individually. They also observed that, in contrast to HIV-specific CD8 T-cells, a high fraction of HIV-specific CD4 T cells that expressed inhibitory receptors also co-expressed CD28. PD-L1 blockade concurrent with CD28 stimulation had an additive effect in enhancing HIV-specific CD4 T-cell proliferation in vitro compared with manipulation of either pathway alone, illustrating that concurrent modulation of inhibitory and stimulatory receptors augmented restoration of HIV-specific CD4 T-cell responses.
A recent study by Quigley et al. [47 ] investigated the transcriptional 'signature' generated by PD-1 in HIVspecific CD8 T cells and found that this signature was highly enriched in progressors as compared with controllers. The authors used gene-set enrichment analyses that allowed them not only to compare transcriptional profiles between data obtained on primary CD8 T cells and transfected model cell lines, but also to perform informative cross-species comparisons with the murine LCMV model [48] . The transcriptional factor BATF was found to be downstream of the PD-1 receptor and to be a key regulator of CD8 T-cell exhaustion. The authors successfully used siRNA knockdown in primary HIV-specific T cells to demonstrate that silencing BATF expression not only restored IFN-g secretion and proliferation by HIV-specific CD8 T cells but also augmented secretion of IL-2 by HIV-specific CD4 T cells, suggesting that BATF may play an important role in the dysregulation of CD4 T cells in HIV infection.
Taken together, these data suggest that as shown for virus-specific CD8 T cells in the murine LCMV model [49 ] , HIV-specific CD4 T cells are controlled by complex layers of negative regulation resulting from the coexpression of multiple inhibitory receptors, and that the sets of inhibitory molecules controlling the CD4 and CD8 T-cell responses are only partially overlapping. Whether manipulation of these immunoregulatory networks can be beneficial in vivo to complement ART or boost vaccine efficacy will require further studies. Careful monitoring of potential autoimmune side effects will be critical, as illustrated by the occurrence of an inflammatory colitis in a cancer patient treated in a recent trial with a blocking anti-PD-1 antibody [50] .
Cytokines and HIV-specific CD4 T-cell impairment: the roles of IL-10 and IL-21
Soluble factors, such as chemokines and cytokines, are both critical mediators of HIV-specific CD4 T-cell functions and key regulators of this lymphocyte subset. Interleukin-10 (IL-10) has been shown to play a critical role in the balance between immunopathology and protective responses in infectious diseases [51, 52] and to facilitate the establishment of chronic infection in the murine LCMV model [53, 54] . In HIV infection, early studies [55, 56] have shown that plasma IL-10 levels increased with disease progression and that IL-10 blockade enhanced HIV Env-specific T-cell proliferative responses in some patients. Brockman et al. [57 ] further clarified the role of the IL-10 pathway in impairment of HIV-specific CD4 T-cell responses. Antibody blockade of the IL-10 receptor (IL-10Ra) not only resulted in increased proliferation but also enhanced secretion of the cytokines IFN-g and IL-2 by HIV-specific CD4 T cells. The effect of IL-10Ra blockade on proliferation correlated with IL-10 plasma levels and IL-10 RNA expression in PBMC. Investigating the source of IL-10, the authors showed that even though monocytes appeared to be the major source of IL-10, a variety of cell subsets contributed to the increased levels of IL-10 in HIV infection. Said et al. [58 ] showed a functional relationship between the IL-10 and PD-1 pathways and established a link to microbial products whose translocation from the gut is thought to play an important role in HIV pathogenesis. The authors demonstrated that microbial products induce expression of PD-1 molecule on monocytes, and expression of PD-1 on these cells correlated with viral load. Triggering PD-1 signaling into monocytes induced IL-10 production. The inhibitory effect that PD-1 signaling into monocytes had on HIVspecific CD4 T-cell proliferative responses was reversed upon IL-10R blockade, showing that the modulation of monocyte antigen-presenting functions by PD-1 is critically mediated by IL-10. This study demonstrates that besides inducing chronic immune activation in HIV infection [59] , bacterial translocation through the damaged intestinal mucosa upregulates inhibitory pathways that impair virus-specific immune responses.
IL-21 is a g-chain cytokine mainly produced by a subset of CD4 T cells, which are now termed T follicular Th cells (Tfh) [60] . IL-21 induces the development of Th17 cells, blocks the differentiation of regulatory T cells [61] , maintains CD8 T-cell function [62] , regulates B-cell differentiation [63, 64] , and is important in regulating effector T cells in the gut [65] . Clinical trials with recombinant IL-21 are ongoing in cancer patients to boost immune responses [66] , while excessive IL-21 production is thought to play a role in several autoimmune diseases [67] .
Studies in the murine LCMV model showed that IL-21 produced by virus-specific CD4 T cells was critical in controlling chronic infection and in preventing exhaustion of CD8 T cells [68 -70 ] . In HIV infection, Iannello et al. [71] observed decreased levels of plasma IL-21 in chronic progressors individuals and found a positive correlation of plasma IL-21 levels with CD4 counts. A subsequent study from the same group showed that only elite controllers maintained normal plasma levels of IL-21 compared with HIV-negative subjects. ART only partially restored production of this cytokine [72] . Stimulated bulk CD4 T cells from chronic progressors produced less IL-21 than CD4 T cells from elite controllers. Recombinant human IL-21 prevented enhanced spontaneous apoptosis of CD4 T cells from HIV-infected patients.
Yue et al. [73] showed that in chronic progressors patients, higher frequencies of IL-21 producing CD4 T cells correlated with lower viral load. However, control of viremia in elite controllers and in ART-treated individuals was associated with low frequency of IL-21-secreting HIV-specific CD4 T cells. In contrast, Chevalier et al. [74 ] , using a different technical approach, found higher levels of IL-21 secretion by HIV-specific CD4 T cells in elite controllers than in ART-controlled individuals, with the lowest levels detected in chronic progressors. Examining mechanisms of T-cell help, the authors found that IL-21 increased perforin, granzyme A and B, and the degranulation marker CD107 in HIV-specific CD8 T cells and that addition of IL-21 increased the capacity of HIV-specific CD8 T cells to inhibit viral replication in vitro [74 ] . These data suggest that HIV-specific IL-21 þ CD4 T cells might contribute to the control of viral replication in humans and be important for an effective vaccine.
Virus-specific CD4 T cells and HIV vaccines
Studies performed in monkeys indicated the importance of cell-mediated immunity that could significantly reduce replication of simian immunodeficiency virus (SIV) [75] [76] [77] [78] . Based on these data and because eliciting broadly neutralizing antibodies has proven to be a very challenging task, the first HIV vaccines were primarily designed to induce HIV-specific CD8 T-cell responses since the prevailing view was that augmenting the CD4 T-cell responses might lead to increased numbers of target cells available for infection [79] .
The failure of the STEP trial [1,2], based on a Ad5 adenoviral vector, was a major setback for the T-cell vaccine strategy. The CD8 T-cell responses generated by this vaccine were weak and narrow [80] . One hypothesis proposed to explain the increased rate of HIV acquisition among vaccinees who had prevaccine anamnestic adenovirus-specific immune responses was the induction of vector-specific CD4 T cells that increased the number of target at mucosal sites [80] . However, recent studies suggest that this hypothesis might not be valid [81] . Major efforts are being dedicated to creating vectors that do not induce vector-specific immune responses [82, 83] and generate broader HIV-specific T-cell responses, including CD4 T-cell responses [84 ] .
The RV144 clinical trial, based on a poxvirus (canarypox/ ALVAC) vector/recombinant gp120 combination, which showed a modest 31.2% efficacy in reducing HIV infection rates, has revived hope of an effective HIV vaccine [3 ]. The correlates of immunity elicited by this vaccine are still not fully characterized. Even though the RV144 was designed to induce strong CD8 T-cell responses, the only HIV-specific T-cell responses found in vaccinees were weak CD4 T-cell proliferative responses [85] suggesting a potentially beneficial role of HIV-specific CD4 T cells in this trial. The RV144 study has strengthened the rationale for testing poxvirus-based vaccines and multiple candidates are now in clinical trials using different vectors and prime-boost regimens [86] . Poxvirus vectors are capable of inducing robust HIV-specific CD4 T-cell responses in humans [87, 88] , but there is currently no evidence that one type of vector is superior to the others to generate effective HIV-specific CD4 T-cell responses.
Conclusion
The interest for the role of CD4 T-cell responses in HIV infection has been reignited in recent years. Besides their critical role in orchestrating the different arms of the immune response, HIV-specific CD4 T cells may also have direct antiviral effector effects. A clarification of the role of HIV-specific CD4 T cells at mucosal sites should be of high priority in future studies. The latest data discussed here suggest that CD4 T cells play an important role in controlling HIV infection and highlight the need for a more vigorous investigation of the HIV-specific CD4 T-cell responses in the perspective of developing an effective HIV vaccine. 
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